MA44251A - Procédés comprenant un dosage intermittent et fixe de cediranib - Google Patents

Procédés comprenant un dosage intermittent et fixe de cediranib

Info

Publication number
MA44251A
MA44251A MA044251A MA44251A MA44251A MA 44251 A MA44251 A MA 44251A MA 044251 A MA044251 A MA 044251A MA 44251 A MA44251 A MA 44251A MA 44251 A MA44251 A MA 44251A
Authority
MA
Morocco
Prior art keywords
cediranib
intermittent
processes including
fixed dosage
dosage
Prior art date
Application number
MA044251A
Other languages
English (en)
French (fr)
Inventor
Simon Barry
Tony Ho
Susan Percy Ivy
Jane Kendrew
Elise Kohn
Jung-Min Lee
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
The Us Secretery Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, The Us Secretery Department Of Health And Human Services filed Critical Astrazeneca Ab
Publication of MA44251A publication Critical patent/MA44251A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA044251A 2016-02-15 2017-02-14 Procédés comprenant un dosage intermittent et fixe de cediranib MA44251A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662295421P 2016-02-15 2016-02-15

Publications (1)

Publication Number Publication Date
MA44251A true MA44251A (fr) 2018-12-26

Family

ID=59625551

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044251A MA44251A (fr) 2016-02-15 2017-02-14 Procédés comprenant un dosage intermittent et fixe de cediranib

Country Status (16)

Country Link
US (1) US20210322415A1 (enExample)
EP (2) EP4071174A1 (enExample)
JP (2) JP6865762B2 (enExample)
KR (1) KR102830910B1 (enExample)
CN (1) CN109073650A (enExample)
AU (1) AU2017221268B2 (enExample)
CA (1) CA3014674C (enExample)
DK (1) DK3417294T3 (enExample)
ES (1) ES2906813T3 (enExample)
HU (1) HUE058114T2 (enExample)
MA (1) MA44251A (enExample)
MX (2) MX2018009867A (enExample)
PL (1) PL3417294T3 (enExample)
RU (1) RU2740849C2 (enExample)
TW (1) TWI827530B (enExample)
WO (1) WO2017142871A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
MA49144A (fr) 2017-05-18 2020-03-25 Tesaro Inc Polythérapies pour le traitement du cancer
CA3076515A1 (en) 2017-09-30 2019-04-04 Tesaro, Inc. Combination therapies for treating cancer
MA50618A (fr) * 2017-10-06 2020-08-12 Tesaro Inc Polyrhérapies et leurs utilisations

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
BRPI0017548B8 (pt) 1999-02-10 2023-05-02 Astrazeneca Ab Composto
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
BR0112225A (pt) 2000-07-07 2003-05-06 Angiogene Pharm Ltd Composto, composição farmacêutica, uso de um composto, e, processo papa preparar um composto
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
MXPA04010199A (es) * 2002-04-15 2005-07-05 Sloan Kettering Inst Cancer Terapia en combinacion para el tratamiento de cancer.
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
JP2008514576A (ja) * 2004-09-27 2008-05-08 アストラゼネカ アクチボラグ Ａｚｄ２１７１およびイマチニブを含む癌組合せ療法
US20090035317A1 (en) * 2007-01-12 2009-02-05 Daugherty Patrick S Peptides binding to vascular endothelial growth factor
CA2715181A1 (en) * 2008-02-21 2009-08-27 Astrazeneca Ab Combination therapy 238
WO2010091140A1 (en) * 2009-02-04 2010-08-12 Bipar Sciences, Inc. Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
HK1201828A1 (en) * 2011-11-08 2015-09-11 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
JP6184423B2 (ja) * 2012-05-18 2017-08-23 大日本住友製薬株式会社 カルボン酸化合物
WO2014066834A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
EP3082853A2 (en) * 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
NO2714752T3 (enExample) * 2014-05-08 2018-04-21
MX389663B (es) * 2014-10-14 2025-03-20 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.

Also Published As

Publication number Publication date
TWI827530B (zh) 2024-01-01
US20210322415A1 (en) 2021-10-21
EP3417294A4 (en) 2019-08-14
CN109073650A (zh) 2018-12-21
TW201906610A (zh) 2019-02-16
CA3014674C (en) 2024-06-18
RU2018131377A3 (enExample) 2020-06-02
JP7271594B2 (ja) 2023-05-11
KR20180125456A (ko) 2018-11-23
ES2906813T3 (es) 2022-04-20
MX2018009867A (es) 2019-05-27
RU2740849C2 (ru) 2021-01-21
JP2019504860A (ja) 2019-02-21
KR102830910B1 (ko) 2025-07-04
MX2023007826A (es) 2023-07-07
JP2021105039A (ja) 2021-07-26
DK3417294T3 (da) 2022-02-21
AU2017221268B2 (en) 2024-02-15
RU2018131377A (ru) 2020-03-17
JP6865762B2 (ja) 2021-04-28
WO2017142871A8 (en) 2018-06-14
WO2017142871A1 (en) 2017-08-24
EP3417294B8 (en) 2022-05-04
CA3014674A1 (en) 2017-08-24
PL3417294T3 (pl) 2022-05-09
EP3417294A1 (en) 2018-12-26
EP3417294B1 (en) 2021-12-01
HUE058114T2 (hu) 2022-07-28
AU2017221268A1 (en) 2018-08-30
EP4071174A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
IL259299B (en) System for determining the health and gender of a chick
EP3720549A4 (en) PATIENT THERAPY SYSTEMS AND METHODS
EP3586113A4 (en) BIOMIMETIC SENSOR PLATFORM UNIT
DK3485237T3 (da) Dosismålesystemer
IL256145B (en) Systems and methods for patient-specific dosing
EP3258883A4 (en) DEVICE, SYSTEMS AND METHOD FOR HEART TREATMENT
EP3303413A4 (en) PROCESS FOR THE PREPARATION OF SUGAMMADEX AND INTERMEDIATE PRODUCTS THEREOF
EP3367987A4 (en) DEVICE AND METHOD FOR WOUND THERAPY
EP3380837A4 (en) TEST DEVICE
IL253612B (en) Delivery of hydrophobic active agent particles
EP3307772A4 (en) TGF-BETA-3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
EP3323516A4 (en) COATING METHOD AND COATING DEVICE
EP3603604A4 (en) MEDICINE RECOGNITION DEVICE, MEDICINAL RECOGNITION METHOD, AND MEDICINAL RECOGNITION PROGRAM
EP3697682A4 (en) METHOD AND DEVICE FOR CONSTRUCTION OF AIRSHIPS
EP3538071A4 (en) PHARMACEUTICAL COMPOUNDING METHODS AND SYSTEMS
DK3701944T3 (da) Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
EP3402540C0 (en) STERILIZATION DEVICE AND METHOD
EP3606465A4 (en) Dosing regimens and related compositions and methods
EP3678089A4 (en) DRUG INSPECTION DEVICE, IMAGE PROCESSING DEVICE, IMAGE PROCESSING PROCESS AND PROGRAM
FR3026303B1 (fr) Procede de sechage de dispositif medical
IL249462A0 (en) A method for determining dosage, a test device, a pattern forming device, a substrate and a method for preparing the device
MA51162A (fr) Schémas posologiques et compositions et procédés associés
EP3675030A4 (en) DRUG INSPECTION ASSISTANT DEVICE, DRUG IDENTIFICATION DEVICE, IMAGE PROCESSING DEVICE, IMAGE PROCESSING PROCESS AND PROGRAM
EP3654673A4 (en) MULTICAST METHOD AND DEVICE
MA44251A (fr) Procédés comprenant un dosage intermittent et fixe de cediranib